🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07742150
Starting soon Not applicable

Placebo Effect in Field-Based Physical Performance

NCT07742150 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-03

Condition(s) studied

Physical PerformancePlacebo EffectCognitive Performance

Investigational drug(s) / intervention(s)

Caffeine (6mg/kg) →Placebo (Starch capsule)Sham (No Treatment)

Caffeine (6mg/kg): Anhydrous caffeine administered in an encapsulated form at a dosage of 6mg per kilogram of body mass, 30-60 minutes before the exercise protocol.

Placebo (Starch capsule): Corn starch administered in an identical encapsulated form as the active caffeine, 30-60 minutes before the exercise protocol.

Sham (No Treatment): Participants perform the same exercise protocols without any capsule or substance administration.

Study summary

This study aims to investigate the placebo (PLA) effect on physical performance across different sports disciplines in real-world, field-based settings. The study investigates how participant expectations and beliefs regarding caffeine (CAF) intake influence physical performance and psychomotor function outside the controlled laboratory environment. Healthy, physically active adults (n = 120) from diverse sports backgrounds will be randomly assigned to receive caffeine, placebo, or no intervention. Participants will perform discipline-specific field exercise tests (e.g., running-based protocols or repeated sprint protocols) while physiological responses are monitored using wearable technology. Physical performance outcomes and psychomotor responses will be analyzed to evaluate the real-world impact of the placebo effect and to distinguish the pharmacological effects of caffeine from those driven by psychological expectations across different athletic settings.

Eligibility

Sex
ALL
Min age
20 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 20 and 35 years, * Healthy adults, * Regular physical activity, * Normal or corrected-to-normal vision, * Habitual caffeine consumption. Exclusion Criteria: * History of neurological, psychiatric, cardiovascular, or metabolic disorders, * Current use of medication or supplements affecting the central nervous system, * Musculoskeletal injuries that would impair physical performance, * No habitual caffeine consumption or severe negative side effects of caffeine, * Diagnosed sleep disorders or chronic fatigue, * Diagnosed major depressive disorder or other severe psychiatric conditions, * Presence of any menstrual disorders, * Inability to attend all experimental study visits.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Poznan University of Physical Education Poznan Greater Poland Voivodeship

More Poznan University of Physical Education trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07742150 on ClinicalTrials.gov ↗ ← All trials in Poland